Treatment decision-making and treatment experiences in men with metastatic castration-resistant prostate cancer
DOI:
https://doi.org/10.2340/1651-226X.2025.42748Keywords:
Castration-resistant, communication, decision-making, prostate neoplasm, therapeuticsAbstract
Background and purpose: For the most advanced stage of metastatic castration-resistant prostate cancer (mCRPC), several life-prolonging treatments have become available over the past decade. Treatment decision-making (TDM) and experiences in this phase are yet to be studied. Hence, this study aimed to describe men’s satisfaction with TDM and treatment experiences during the first 12 months of a life-prolonging treatment of mCRPC.
Patients and methods: This prospective study included 104 men with mCRPC who started and remained on the same life-prolonging treatment for 12 months. They received a questionnaire on TDM, treatment experiences, and well-being every 3 months. Correlation analyses explored associations between satisfaction with TDM at baseline and treatment experiences and well-being over time.
Results and interpretation: The participants (median age: 77 years) generally reported high satisfaction with physician- and nurse communication and confidence/trust at baseline (>55% reported the highest satisfaction in all questions), but lower satisfaction with communication regarding how the treatments could affect them – up to 40% reported not having talked about that at all. Treatment experiences and physical- and emotional well-being remained stable over time. Associations were found between satisfaction with TDM at baseline and how they rated the treatment as a whole at six months, and well-being at six and 12 months. In mCRPC, men’s TDM preferences need to be explored, and shared decision-making needs to be facilitated when considering treatment. Furthermore, clinicians need to discuss how the treatment might affect patients’ everyday lives when discussing life-prolonging treatments with them.
Downloads
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.
https://doi.org/10.3322/caac.21834 DOI: https://doi.org/10.3322/caac.21834
Doveson SE, Holm M, Fransson P, Wennman-Larsen A. Identification of early symptoms and changes in QoL and functioning among men with primary localized prostate cancer who later develop metastases: A matched, prospective study. Palliat Support Care. 2022;21(2):230–8.
https://doi.org/10.1017/S1478951522000074 DOI: https://doi.org/10.1017/S1478951522000074
Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.
https://doi.org/10.1056/NEJMoa040720 DOI: https://doi.org/10.1056/NEJMoa040720
Sumanasuriya S, De Bono J. Treatment of advanced prostate cancer – a review of current therapies and future promise. Cold Spring Harbor Perspect Med. 2018;8(6)1–13.
https://doi.org/10.1101/cshperspect.a030635 DOI: https://doi.org/10.1101/cshperspect.a030635
De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.
https://doi.org/10.1056/NEJMoa1014618 DOI: https://doi.org/10.1056/NEJMoa1014618
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.
https://doi.org/10.1056/NEJMoa1207506 DOI: https://doi.org/10.1056/NEJMoa1207506
Cornford P, Van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: Treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263–82.
https://doi.org/10.1016/j.eururo.2020.09.046 DOI: https://doi.org/10.1016/j.eururo.2020.09.046
Doveson S, Holm M, Axelsson L, Fransson P, Wennman-Larsen A. Facing life-prolonging treatment: the perspectives of men with advanced metastatic prostate cancer – an interview study. Eur J Oncol Nurs. 2020;49:101859.
https://doi.org/10.1016/j.ejon.2020.101859 DOI: https://doi.org/10.1016/j.ejon.2020.101859
Wagland R, Nayoan J, Matheson L, Rivas C, Brett J, Downing A, et al. ‘Very difficult for an ordinary guy’: factors influencing the quality of treatment decision-making amongst men diagnosed with localised and locally advanced prostate cancer: findings from a UK-wide mixed methods study. Patient Educ Couns. 2019;102(4):797–803.
https://doi.org/10.1016/j.pec.2018.12.004 DOI: https://doi.org/10.1016/j.pec.2018.12.004
Myers RE, Leader AE, Censits JH, Trabulsi EJ, Keith SW, Petrich AM, et al. Decision support and shared decision making about active surveillance versus active treatment among men diagnosed with low-risk prostate cancer: a pilot study. J Cancer Educ. 2018;33(1):180–5.
https://doi.org/10.1007/s13187-016-1073-7 DOI: https://doi.org/10.1007/s13187-016-1073-7
Hoffman RM, Van Den Eeden SK, Davis KM, Lobo T, Luta G, Shan J, et al. Decision-making processes among men with low-risk prostate cancer: a survey study. Psycho-oncology. 2018;27(1):325–32.
https://doi.org/10.1002/pon.4469 DOI: https://doi.org/10.1002/pon.4469
Cuypers M, Lamers RED, Cornel EB, Van de Poll-Franse LV, De Vries M, Kil PJM. The impact of prostate cancer diagnosis and treatment decision-making on health-related quality of life before treatment onset. Support Care Cancer. 2018;26(4):1297–304.
https://doi.org/10.1007/s00520-017-3953-8 DOI: https://doi.org/10.1007/s00520-017-3953-8
Tariman JD, Berry DL, Cochrane B, Doorenbos A, Schepp K. Preferred and actual participation roles during health care decision making in persons with cancer: a systematic review. Ann Oncol. 2010;21(6):1145–51.
https://doi.org/10.1093/annonc/mdp534 DOI: https://doi.org/10.1093/annonc/mdp534
Herrmann A, Hall A, Sanson-Fisher R, Zdenkowski N, Watson R, Turon H. Not asking cancer patients about their preferences does make a difference. A cross-sectional study examining cancer patients’ preferred and perceived role in decision-making regarding their last important cancer treatment. Eur J Cancer Care (Engl). 2018;27(5):e12871.
https://doi.org/10.1111/ecc.12871 DOI: https://doi.org/10.1111/ecc.12871
Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (Or it takes at least two to tango). Soc Sci Med. 1997;44(5):681–92.
https://doi.org/10.1016/S0277-9536(96)00221-3 DOI: https://doi.org/10.1016/S0277-9536(96)00221-3
Sorensen von Essen H, Piil K, Dahl Steffensen K, Rom Poulsen F. Shared decision making in high-grade glioma patients – a systematic review. Neuro-oncology Pract. 2020;7(6):589–98.
https://doi.org/10.1093/nop/npaa042 DOI: https://doi.org/10.1093/nop/npaa042
Shen MJ, Nelson CJ, Peters E, Slovin SF, Hall SJ, Hall M, et al. Decision-making processes among prostate cancer survivors with rising PSA levels: results from a qualitative analysis. Med Decis Making Int J Soc Med Decis Making. 2015;35(4):477–86.
https://doi.org/10.1177/0272989X14558424 DOI: https://doi.org/10.1177/0272989X14558424
Atherton PJ, Smith T, Singh JA, Huntington J, Diekmann BB, Huschka M, et al. The relation between cancer patient treatment decision-making roles and quality of life. Cancer. 2013;119(12):2342–9.
https://doi.org/10.1002/cncr.28046 DOI: https://doi.org/10.1002/cncr.28046
Hoffman RM, Lo M, Clark JA, Albertsen PC, Barry MJ, Goodman M, et al. Treatment decision regret among long-term survivors of localized prostate cancer: Results from the prostate cancer outcomes study. J Clin Oncol. 2017;35(20):2306–14.
https://doi.org/10.1200/JCO.2016.70.6317 DOI: https://doi.org/10.1200/JCO.2016.70.6317
Wollersheim BM, Van Stam MA, Bosch R, Pos FJ, Tillier CN, Van der Poel HG, et al. Unmet expectations in prostate cancer patients and their association with decision regret. J Cancer Surviv. 2020;14(5):731–8.
https://doi.org/10.1007/s11764-020-00888-6 DOI: https://doi.org/10.1007/s11764-020-00888-6
Berry DL, Hong F, Blonquist TM, Halpenny B, Xiong N, Filson CP, et al. Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: results from a multi-site randomized trial. Urol Oncol. 2021;39(8):493.e9–493.e15.
https://doi.org/10.1016/j.urolonc.2020.11.038 DOI: https://doi.org/10.1016/j.urolonc.2020.11.038
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.
https://doi.org/10.1200/JCO.1993.11.3.570 DOI: https://doi.org/10.1200/JCO.1993.11.3.570
Bonomi AE, Cella DF, Hahn EA, Bjordal K, Sperner-Unterweger B, Gangeri L, et al. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res. 1996;5(3):309–20.
https://doi.org/10.1007/BF00433915 DOI: https://doi.org/10.1007/BF00433915
Brédart A, Bottomley A, Blazeby JM, Conroy T, Coens C, D’Haese S, et al. An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32). Eur J Cancer. 2005;41(14):2120–31.
https://doi.org/10.1016/j.ejca.2005.04.041 DOI: https://doi.org/10.1016/j.ejca.2005.04.041
Peipert JD, Beaumont JL, Bode R, Cella D, Garcia SF, Hahn EA. Development and validation of the functional assessment of chronic illness therapy treatment satisfaction (FACIT TS) measures. Qual Life Res. 2014;23(3):815–24.
https://doi.org/10.1007/s11136-013-0520-8 DOI: https://doi.org/10.1007/s11136-013-0520-8
Fonteyn ME, Kuipers B, Grobe SJ. A description of think aloud method and protocol analysis. Qual Health Res. 1993;3(4):430–41.
https://doi.org/10.1177/104973239300300403 DOI: https://doi.org/10.1177/104973239300300403
Doveson S. Experiences of living with, and undergoing treatment of, metastastic, castration-resistant prostate cancer – a qualitative study. Master’s thesis. Stockholm, Sweden: Sophiahemmet University; 2014.
Song L, Chen RC, Bensen JT, Knafl GJ, Nielsen ME, Farnan L, et al. Who makes the decision regarding the treatment of clinically localized prostate cancer – the patient or physician?: Results from a population-based study. Cancer. 2013;119(2):421–8.
https://doi.org/10.1002/cncr.27738 DOI: https://doi.org/10.1002/cncr.27738
Orom H, Homish DL, Homish GG, Underwood W, 3rd. Quality of physician-patient relationships is associated with the influence of physician treatment recommendations among patients with prostate cancer who chose active surveillance. Urol Oncol. 2014;32(4):396–402.
https://doi.org/10.1016/j.urolonc.2013.09.018 DOI: https://doi.org/10.1016/j.urolonc.2013.09.018
Renzi C, Fioretti C, Oliveri S, Mazzocco K, Zerini D, Alessandro O, et al. A qualitative investigation on patient empowerment in prostate cancer. Front Psychol. 2017;8:1215.
https://doi.org/10.3389/fpsyg.2017.01215 DOI: https://doi.org/10.3389/fpsyg.2017.01215
Nakayama K, Osaka W, Matsubara N, Takeuchi T, Toyoda M, Ohtake N, et al. Shared decision making, physicians’ explanations, and treatment satisfaction: a cross-sectional survey of prostate cancer patients. BMC Med Inform Decis Making. 2020;20(1):334.
https://doi.org/10.1186/s12911-020-01355-z DOI: https://doi.org/10.1186/s12911-020-01355-z
Elwyn G, Lloyd A, May C, Van der Weijden T, Stiggelbout A, Edwards A, et al. Collaborative deliberation: a model for patient care. Patient Educ Couns. 2014;97(2):158–64.
https://doi.org/10.1016/j.pec.2014.07.027 DOI: https://doi.org/10.1016/j.pec.2014.07.027
Løwe MM, Osther PJS, Ammentorp J, Birkelund R. The balance of patient involvement: patients’ and health professionals’ perspectives on decision-making in the treatment of advanced prostate cancer. Qual Health Res. 2021;31(1):29–40.
https://doi.org/10.1177/1049732320962759 DOI: https://doi.org/10.1177/1049732320962759
Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy – prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health. 2009;12(1):124–9.
https://doi.org/10.1111/j.1524-4733.2008.00409.x DOI: https://doi.org/10.1111/j.1524-4733.2008.00409.x
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Sandra Doveson, Per Fransson, Lena Axelsson, Agneta Wennman-Larsen
This work is licensed under a Creative Commons Attribution 4.0 International License.
